Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 10.55M
Average 10.19M
ALLO Net Income
Bottom-line profit after all expenses, interest, and taxes.
Allogene Therapeutics, Inc.NASDAQ: ALLO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$42.61M, compared with -$59.73M a year earlier. Trailing-twelve-month net income was -$173.76M.
Context
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$130.96M (+31.4%) for the fiscal year ending Dec 2026, a step up from the +25.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$42.61M-9.8% QoQ
- Last fiscal yearDec 2025
- -$190.89M+25.9% YoY
- LTMMar 2026
- -$173.76M+31.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +28.7% | -16.4% | -45.1 pp |
| 1 year | +25.9% | +31.4% | +5.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (190.89M) USD
- Year-over-year change
- +25.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (190.89M) | +25.9% |
| FY2024 | 2024-12-31 | (257.59M) | +21.3% |
| FY2023 | 2023-12-31 | (327.27M) | +3.9% |
| FY2022 | 2022-12-31 | (340.41M) | -87.0% |
| FY2021 | 2021-12-31 | (182.05M) | — |
Net Income vs competitors
How ALLO compares with its peers on the latest reported figures
- ALLO's LTM Mar 2026 net income of -$173.76M is the 8th highest of the 9 companies compared; the peer median is -$99.75M.
- Its year-over-year change of +31.1% is the 2nd highest of 9, against a peer median of -16.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$9.47M | +39.5% | — | 40.9% | |
| LTM Mar 2026 | -$44.49M | -102.3% | — | 98.7% | |
| LTM Mar 2026 | -$67.29M | -11.2% | — | 98.8% | |
| LTM Dec 2025 | -$91.71M | -58.4% | — | 345.4% | |
| LTM Mar 2026 | -$107.78M | -391.1% | — | — | |
| LTM Mar 2026 | -$129.91M | +26.1% | — | 2056.8% | |
| LTM Mar 2026 | -$133.22M | +9.9% | — | 1189.1% | |
| LTM Mar 2026 | -$173.76M | +31.1% | — | — | |
| LTM Mar 2026 | -$288.83M | -21.3% | — | 312.0% | |
| Peer median (excluding ALLO) | -$99.75M | -16.2% | — | 312.0% | |
Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 114.09M | 156K | 95K | 22K | 0 |
| Cost of Revenue | 0 | 14.3M | 0 | 0 | 12.36M |
| Gross Profit | 114.09M | (14.14M) | 95K | 22K | (12.36M) |
| Gross Margin | 100.0% | -9063.5% | 100.0% | 100.0% | — |
| Research & Development | 220.18M | 256.39M | 242.91M | 192.3M | 150.15M |
| Selling, General & Admin | 74.11M | 79.31M | 71.67M | 65.21M | 56.78M |
| Operating Expenses | 294.28M | 321.4M | 327.83M | 273.22M | 194.57M |
| Depreciation & Amortization | 10.45M | 14.3M | 14.2M | 13.64M | 12.36M |
| EBITDA | (171.6M) | (326.12M) | (313.07M) | (243.33M) | (177.45M) |
| EBITDA Margin | -150.4% | -209050.6% | -329543.2% | -1106031.8% | — |
| Operating Income | (180.19M) | (335.54M) | (327.74M) | (273.2M) | (206.93M) |
| Operating Margin | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — |
| Interest Income | 1.71M | 4.57M | 18.31M | 20.15M | 19.29M |
| Interest Expense | 0 | 0 | 0 | 181K | 1.08M |
| Other Income / Expenses | (1.86M) | (4.88M) | 472K | 16.05M | 16.05M |
| Income Before Tax | (182.05M) | (340.41M) | (327.27M) | (257.15M) | (190.89M) |
| Pre-Tax Margin | -159.6% | -218214.1% | -344489.5% | -1168850.0% | — |
| Income Tax Expense | 0 | 0 | 0 | 443K | 0 |
| Net Income | (182.05M) | (340.41M) | (327.27M) | (257.59M) | (190.89M) |
| Net Margin | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
| EPS (Basic) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| EPS (Diluted) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| Weighted Avg Shares | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
| Weighted Avg Shares (Diluted) | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
Allogene Therapeutics, Inc.
NASDAQ:ALLO
Intrinsic Alpha fair value
Locked
Current Price
$0.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.